Holen Sie sich die Stockscreener-App
10.81
0.23%
0.025
Handel nachbörslich:
10.95
0.14
+1.30%
Schlusskurs vom Vortag:
$10.79
Offen:
$10.84
24-Stunden-Volumen:
45,703
Relative Volume:
1.71
Marktkapitalisierung:
$21.26M
Einnahmen:
-
Nettoeinkommen (Verlust:
$-4.85M
KGV:
-34.87
EPS:
-0.31
Netto-Cashflow:
$-3.95M
1W Leistung:
-11.83%
1M Leistung:
-12.47%
6M Leistung:
-45.65%
1J Leistung:
+63.79%
1-Tages-Spanne:
$10.45
$10.98
1-Wochen-Bereich:
$10.45
$12.26
52-Wochen-Spanne:
$5.70
$22.90
Cadrenal Therapeutics Inc Stock (CVKD) Company Profile
Firmenname
Cadrenal Therapeutics Inc
Sektor
Branche
Telefon
904-300-0701
Adresse
822 A1A NORTH, PONTE VEDRA
Vergleichen Sie CVKD mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
CVKD
Cadrenal Therapeutics Inc
|
10.81 | 24.11M | 0 | -4.85M | -3.95M | -0.31 |
|
VRTX
Vertex Pharmaceuticals Inc
|
470.13 | 119.21B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
560.93 | 59.16B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
325.28 | 40.57B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ARGX
Argen X Se Adr
|
571.23 | 34.02B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ONC
Beone Medicines Ltd Adr
|
295.59 | 29.19B | 3.81B | -644.79M | -669.77M | -6.24 |
Cadrenal Therapeutics Inc Stock (CVKD) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2023-12-18 | Eingeleitet | Noble Capital Markets | Outperform |
Cadrenal Therapeutics Inc Aktie (CVKD) Neueste Nachrichten
Cadrenal Therapeutics Inc. Stock Analysis and ForecastFree Market Dynamics Reports - jammulinksnews.com
What drives Cadrenal Therapeutics Inc. stock priceTremendous growth opportunities - jammulinksnews.com
Is Cadrenal Therapeutics Inc. a good long term investmentHigh-yield market plays - jammulinksnews.com
What analysts say about Cadrenal Therapeutics Inc. stockConsistently outstanding ROI - jammulinksnews.com
Outlook Therapeutics Inc. Stock Analysis and ForecastExplosive market performance - jammulinksnews.com
(CVKD) Technical Pivots with Risk Controls - news.stocktradersdaily.com
What analysts say about TLSA stockOutstanding risk-reward balance - PrintWeekIndia
Cadrenal Therapeutics Director Resignation Announced - The Globe and Mail
Future of HOHOHO V2.0(santa floki v2) ExplainedEarly Breakout Tracker - Newser
Cadrenal Therapeutics director resigns; annual meeting set for September - Investing.com
Candel Therapeutics (CADL) Shares Soar 9.60% - AInvest
What makes Cadrenal Therapeutics Inc. stock price move sharplyFree Capital Allocation Plans - Newser
How Cadrenal Therapeutics Inc. stock performs during market volatilityRisk Adjusted Stock Signals - Newser
Why Cadrenal Therapeutics Inc. stock attracts strong analyst attention10x Return With Managed Risk - Newser
Why Restaurant Brands International Inc. stock attracts strong analyst attentionFree Access to Community - Newser
(CVKD) Proactive Strategies - news.stocktradersdaily.com
Cadrenal Therapeutics (NASDAQ:CVKD) Trading 2.3% Higher – Here’s What Happened - Defense World
Why Did Cadrenal Therapeutics Soar 11.78%? - AInvest
(CVKD) Long Term Investment Analysis - news.stocktradersdaily.com
Pre-market Movers: XCUR, KLTO, INMB, SERA... - RTTNews
Cadrenal Therapeutics (NASDAQ:CVKD) Shares Down 0.1% – Here’s What Happened - Defense World
Cadrenal Therapeutics Highlights New Research on Anticoagulation Burden for LVAD Patients - BioSpace
Cadrenal Therapeutics to Engage Potential Partners at BIO International Convention 2025 - BioSpace
What is Zacks Small Cap’s Estimate for CVKD FY2025 Earnings? - Defense World
CVKD: Preparations Continue for Phase 3 Trial of Tecarfarin… - MSN
CVKD: Preparations Continue for Phase 3 Trial of Tecarfarin - research-tree.com
Cadrenal Therapeutics (NASDAQ:CVKD) Earns Buy Rating from HC Wainwright - Defense World
Positive Outlook for Cadrenal Therapeutics, Inc. Amid Strategic Developments and FDA Trial Milestone - TipRanks
Cadrenal Therapeutics (CVKD) Receives Buy Rating from HC Wainwright & Co. | CVKD Stock News - GuruFocus
Cadrenal Therapeutics advances in tecarfarin production By Investing.com - Investing.com Nigeria
Finanzdaten der Cadrenal Therapeutics Inc-Aktie (CVKD)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.51%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):